Screener
Celldex Therapeutics CLDX Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $47,454 | $28,871 |
| Marketable securities | 670,133 | 489,702 |
| Accounts and other receivables | 230 | 2,015 |
| Prepaid and other current assets | 7,114 | 14,076 |
| Total current assets | 724,931 | 534,664 |
| Property and equipment, net | 9,756 | 5,334 |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's short-term investments?
- Celldex Therapeutics (CLDX) reported short-term investments of $670.13M in Q2 2026.
- How has Celldex Therapeutics's short-term investments changed year-over-year?
- Celldex Therapeutics's short-term investments increased by 10.3% year-over-year, from $607.29M to $670.13M.
- What is the long-term trend for Celldex Therapeutics's short-term investments?
- Over 5 years (2020 to 2025), Celldex Therapeutics's short-term investments has grown at a 26.6% compound annual growth rate (CAGR), from $150.59M to $489.7M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Celldex Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude